Eli Lilly has told about 50 hospitals to submit comprehensive 340B claims data by June 8 or risk losing mandated 340B price breaks on Lilly medications.
The company announced in January that it would require covered entities to submit claims‑level data for all of its drugs dispensed under 340B, and is now enforcing that deadline.
Eli Lilly says this data is needed to track duplicate discounts and program abuses, but hospitals and the AHA argue the requirement is costly, unworkable, and unlawful.
The American Hospital Association has urged the Health Resources and Services Administration (HRSA) to block Lilly’s policy and is warning that patients and vulnerable communities will be harmed if 340B discounts are cut off over this data dispute.
Sources:
Eli Lilly tells hospitals to submit claims data in days or lose 340B ...
Novo Nordisk Expands 340B Claims Reporting Requirements
Eli Lilly issues data sharing ultimatum to 340B hospitals
Eli Lilly issues data sharing ultimatum to 340B hospitals
Drug Manufacturers Impose New 340B Data-Reporting ...
Hospitals lodge another 340B complaint
Eli Lilly Announces Covered Entities Must Submit Claims Data for All ...
RWC-340B Objects to Eli Lilly's Claims Submission ...
AHA Urges HRSA to Block Eli Lilly's Latest 340B Policy
[PDF] Update to Lilly's Contract Pharmacy Limited Distribution System ...
Eli Lilly moves to deny 340B pricing over data requirements; AHA urges federal action | AHA News
AHA Statement on Eli Lilly Decision To Move Forward With Policy To ...
340B Manufacturer Data Demands: What Covered Entities and ...
AHA Urges HRSA to Block Eli Lilly's Latest 340B Policy
AHA urges HRSA to stop Eli Lilly's 340B claims-data submission ...